---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-031694"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:25:33.714472+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium Q1 revenue up 9% to $193.5M; JORNAY PM +36%; FY guidance reaffirmed; AZSTARYS deal on track

## Summary
- Product net revenue of $193.5M (+9% YoY); GAAP diluted EPS $0.40; adjusted EPS $1.76.
- JORNAY PM net revenue $38.9M (+36% YoY); prescriptions rose 14% to >206,000.
- Pain portfolio net revenue $154.6M (+4% YoY); Belbuca $52.6M, Xtampza ER $50.8M.
- Reaffirmed FY 2026 guidance: product revenue $805-825M, adjusted EBITDA $455-475M.
- Acquisition of AZSTARYS for $650M cash on track to close Q2 2026; $135M milestone potential.

## SEC filing metadata
- accession: 0001628280-26-031694
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000162828026031694/0001628280-26-031694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000162828026031694/coll-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-031694
- JSON: https://secwatch.observer/filing/0001628280-26-031694.json
- Plain text: https://secwatch.observer/filing/0001628280-26-031694.txt

## Source-grounded claims
- claim_id: 93bc5cfc037d4ce7edf0c81a9d21c6077bf85777
  claim: COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended March 31, 2026 results: revenue $193.5 million. Guidance reaffirmed.
  evidence_excerpt: on Form 8-K. --- EX-99.1 (EX-99.1) --- Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress – Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS ® in Second Quarter of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000162828026031694/0001628280-26-031694-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.